Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart’s Top Stock Pick. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Alpine Immune Sciences Inc (ALPN)

Alpine Immune Sciences Inc (ALPN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Alpine Immune Sciences Provides Corporate Update and Reports Second Quarter 2022 Financial Results

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today provided...

ALPN : 8.80 (+2.56%)
Just – Evotec Biologics and Alpine Immune Sciences Expand Partnership for Commercial Process Development of ALPN-303

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and Alpine Immune Sciences, Inc. (NASDAQ: ALPN) today announced that Evotec’s Seattle-based subsidiary, Just –...

EVO : 13.97 (+6.32%)
ALPN : 8.80 (+2.56%)
Alpine Immune Sciences Announces Participation in Fireside Chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced...

ALPN : 8.80 (+2.56%)
Stevanato Group (STVN) Q2 Earnings and Revenues Beat Estimates

Stevanato (STVN) delivered earnings and revenue surprises of 8.33% and 5.18%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

STVN : 18.22 (+0.66%)
ALPN : 8.80 (+2.56%)
Alpine Immune Sciences Appoints Jörn Drappa, MD, PhD, to Board of Directors

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced...

ALPN : 8.80 (+2.56%)
Revolution Medicines, Inc. (RVMD) Surges 5.6%: Is This an Indication of Further Gains?

Revolution Medicines, Inc. (RVMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in...

RVMD : 25.43 (+8.21%)
ALPN : 8.80 (+2.56%)
Alpine Immune Sciences Appoints Andrew S. Sandler, M.D. as Chief Medical Officer

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced...

ALPN : 8.80 (+2.56%)
Alpine Immune Sciences Announces Update on ALPN-303, a Dual BAFF/APRIL Inhibitor for Systemic Lupus Erythematosus and Other Autoimmune and Inflammatory Diseases, at EULAR 2022

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced...

ALPN : 8.80 (+2.56%)
Alpine Immune Sciences Announces Presentations at the 2022 EULAR and ASCO Annual Meetings

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced...

ALPN : 8.80 (+2.56%)
Alpine Immune Sciences Announces FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced...

ALPN : 8.80 (+2.56%)

Barchart Exclusives

Silver Makes A Comeback
Silver tends to be far more volatile than gold. While gold reached a low on July 21 and reversed, silver reached its most recent bottom on July 14, 2022. Since mid-July, silver has outperformed gold on a percentage basis which tends to be a bullish sign for the precious metals. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar